Translational Medicine and Therapeutics Working Group
September 14, 2010

Arthur Rubenstein, M.B.B.Ch.
Executive Vice President of the University of Pennsylvania for Health System and Dean of the University of Pennsylvania School of Medicine
TMAT Working Group Charge

• Identify the attributes, activities, and functional capabilities of an effective translational medicine program for advancing therapeutics development; and

• Broadly assess, from a high-level view, the NIH landscape for extant programs, networks, and centers for inclusion in this network and recommend their optimal organization
# TMAT Working Group Roster

## Non-Federal
- Arthur Rubenstein, MBBCh *(Chair)*
- William Brody, MD, PhD
- Gail Cassell, PhD
- William Roper MD, MPH
- Solomon Snyder, MD
- Huda Zoghbi, MD
- Norman Augustine *(ad hoc)*

## Federal
- Josephine Briggs, MD
- Anthony Fauci, MD
- Stephen Katz, MD, PhD
- Griffin Rodgers, MD MACP
- Susan B. Shurin, MD
- Harold Varmus, MD
- Francis Collins, MD, PhD *(ex officio)*
TMAT Working Group Considerations

- The Working Group will consider how the Agency could leverage and organize a wide range of existing NIH resources and effectively implement the Cures Acceleration Network.

- In addressing its charge, the Working Group will consider:
  - Current NIH-supported infrastructure, initiatives, and resources with direct relevance to the therapeutics development pipeline.
  - Methods to synergize, and avoid competition with, resources in the private sector.
In addressing its charge, the Working Group will consider:

– Prior recommendations for strengthening the clinical and translational research enterprise at NIH, including recommendations of the IOM, and relevant lessons learned from industry, academia, non-profit organizations, etc.; and

– Metrics and methodologies that could be used for evaluating the impact of changes in the organization and management of the therapeutics development program
TMAT Working Group Deliverables

• The Working Group’s report to the full board will include:
  – Description of attributes, activities, and associated functional capabilities of a translational medicine program optimized to enhance therapeutics development;
  – Recommendations for organizing the Agency’s existing components to optimize a translational medicine and therapeutics program; and
  – Metrics for evaluating successes and any untoward consequences of organizational and/or management changes, in particular consequences for the progress of research in areas affected by the proposed changes.
TMAT Consultation: Agenda Overview

• Session I
  – New Paradigm Opportunities for Translational Medicine and Therapeutics Discovery: Establishing A Role for NIH

• Session II
  – Bridging the Gap: Defining and Understanding the Necessary NIH Capabilities and Infrastructure

• Session III
  – Cultivating Partnerships: Setting Goals and Defining Success

• Session IV
  – Engaging in a Dialogue with the Public